BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Larussa T, Basile A, Palleria C, Iannelli C, Vero A, Giubilei L, De Sarro C, Suraci E, Marasco R, Imeneo M, Russo E, Abenavoli L, De Sarro G, Luzza F. Real-life burden of adverse reactions to biological therapy in inflammatory bowel disease: a single-centre prospective case series. Med Pharm Rep 2021;94:289-97. [PMID: 34430850 DOI: 10.15386/mpr-1897] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Tallarico M, Palleria C, Ruffolo L, Spagnuolo R, Naturale MD, De Francesco AE, De Sarro C, Romeo R, Citraro R, Doldo P, Abenavoli L, Gallelli L, Luzza F, Leo A, De Sarro G. Biologics for Inflammatory Bowel Disease in Clinical Practice: A Calabria (Southern Italy) Prospective Pharmacovigilance Study. Pharmaceutics 2022;14. [PMID: 36432640 DOI: 10.3390/pharmaceutics14112449] [Reference Citation Analysis]
2 Sudhakar P, Keersmaekers B, Stiers R, De Dycker E, Geens P, Paps A, Lambrechts T, Wellens J, Sabino J, Ferrante M, Vermeire S, Verstockt B, Limdi JK. Profiling the Use of Complementary Alternative Medicines among Inflammatory Bowel Disease Patients: Results from a Single Center Survey. GastroHep 2022;2022:1-10. [DOI: 10.1155/2022/9919542] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 . Adalimumab/golimumab/infliximab. Reactions Weekly 2022;1905:18-18. [DOI: 10.1007/s40278-022-14408-6] [Reference Citation Analysis]